135 related articles for article (PubMed ID: 35689885)
21. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
22.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
23. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
Ebbing EA; Medema JP; Damhofer H; Meijer SL; Krishnadath KK; van Berge Henegouwen MI; Bijlsma MF; van Laarhoven HW
Oncotarget; 2016 Mar; 7(9):10243-54. PubMed ID: 26863569
[TBL] [Abstract][Full Text] [Related]
24. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
26. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
27. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
28. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Bartley AN; Washington MK; Colasacco C; Ventura CB; Ismaila N; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
J Clin Oncol; 2017 Feb; 35(4):446-464. PubMed ID: 28129524
[TBL] [Abstract][Full Text] [Related]
29. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
Maron SB; Moya S; Morano F; Emmett MJ; Chou JF; Sabwa S; Walch H; Peterson B; Schrock AB; Zhang L; Janjigian YY; Chalasani S; Ku GY; Disel U; Enzinger P; Uboha N; Kato S; Yoshino T; Shitara K; Nakamura Y; Saeed A; Kasi PM; Chao J; Lee J; Capanu M; Wainberg Z; Petty R; Pietrantonio F; Klempner SJ; Catenacci DVT
J Clin Oncol; 2022 Aug; 40(22):2458-2467. PubMed ID: 35349370
[TBL] [Abstract][Full Text] [Related]
30. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
31. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma.
Curea FG; Hebbar M; Ilie SM; Bacinschi XE; Trifanescu OG; Botnariuc I; Anghel RM
Cancer Biother Radiopharm; 2017 Dec; 32(10):351-363. PubMed ID: 29265917
[TBL] [Abstract][Full Text] [Related]
32. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
33. Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy - An Update.
Wöll E; Amann A; Eisterer W; Gerger A; Grünberger B; Rumpold H; Weiss L; Winder T; Greil R; Prager GW
Anticancer Res; 2023 Jul; 43(7):2889-2897. PubMed ID: 37351962
[TBL] [Abstract][Full Text] [Related]
34. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
35. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
36. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
37. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
38. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
39. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
40. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
